NASDAQ
Immunic, Inc. (IMUX)
♥ 537 Thanks from members
Immunic, Inc. (IMUX) exhibits strongly positive net sentiment, driven by anticipated Phase 3 multiple sclerosis data for vidofludimus calcium by year-end 2026, substantial financing, and favorable Wall Street consensus price targets.